



## New Drug

# Landiolol (Rapiblyk)



### Why it matters:

Using rapid-acting IV beta-blockers for some abnormal heart rhythms can help treat patients quicker and allow them to transfer out of intensive care units faster. Landiolol is a continuously infused beta-blocker similar to esmolol, but its clearance half-life (4 minutes) is twice as fast.



### What else to know:

It is the only available beta-blocker that comes as a powder vial that requires reconstitution. Similar to other IV beta-blockers, treat it as a high alert medication.

<b>Manufacturer</b>	AOP Orphan Pharmaceuticals
<b>Approved use</b>	Short-term reduction of ventricular rate in adults with supraventricular tachycardia, including atrial fibrillation and atrial flutter
<b>Approval date</b>	November 2024
<b>Anticipated availability</b>	Available now
<b>Dosage and administration</b>	<p><u>Normal cardiac function</u>: Start at 9 mcg/kg/min and titrate in 9 mcg/kg/min increments every 10 minutes as needed</p> <p><u>Impaired cardiac function (heart failure, etc)</u>: Start at 1 mcg/kg/min and titrate in 1 mcg/kg/min increments every 15 minutes as needed</p> <p><u>Maximum dose</u>: 36 mcg/kg/min (regardless of cardiac function), and limit treatment duration to no more than 24 hours</p>
<b>Storage requirements</b>	<ul style="list-style-type: none"> <li>• Store unopened vials at room temperature (20 to 25°C)</li> <li>• Beyond-use dates at 25°C depend on the reconstitution diluent: <ul style="list-style-type: none"> <li>◦ Sodium chloride 0.9%: 4 hours</li> <li>◦ Dextrose 5%: 48 hours</li> </ul> </li> </ul>
<b>Prescribing information</b>	<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217202s000lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217202s000lbl.pdf</a>



## New Drug

# Landiolol (Rapiblyk)

### References:

- Cafaro T, Allwood M, McIntyre WF, et al. Landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis. *Can J Anaesth*. 2023 Nov;70(11):1828-1838.
- Levy B, Slama M, Lakbar I, et al. Landiolol for Treatment of New-Onset Atrial Fibrillation in Critical Care: A Systematic Review. *J Clin Med*. 2024 May 17;13(10):2951.
- Fellahi JL, Heringlake M, Knotzer J, et al. Landiolol for managing atrial fibrillation in post-cardiac surgery. *Eur Heart J Suppl*. 2018 Jan;20(Suppl A):A4-A9.
- Product information for landiolol (Rapiblyk). AOP Orphan Pharmaceuticals GmbH. 1190 Vienna, Austria. November 2024.

*Users of this resource are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication.*

Copyright © 2025 by Therapeutic Research Center. All Rights Reserved. trchealthcare.com

## Atrial Fibrillation: Focus on Pharmacotherapy

full update July 2025

The FAQ below addresses common clinical questions about the pharmacotherapy of atrial fibrillation, with a focus on drugs for anticoagulation, rate control, and rhythm control. Also included are separate charts comparing drugs for rate control and antiarrhythmics.

Question	Answer/Pertinent Information
<b>ANTICOAGULATION</b>	
For which patients with A-fib/A-flutter should an antithrombotic be considered?	<ul style="list-style-type: none"> <li>Decisions about antithrombotic therapy should be individualized.<sup>2,10</sup> Consider stroke risk, bleeding risk, and patient preference.<sup>10</sup></li> <li>Anticoagulation is recommended for A-fib (or A-flutter) with: <ul style="list-style-type: none"> <li>prior stroke or TIA.<sup>2</sup> Consider initiation within 24 hours of TIA onset. Post-stroke, timing depends on NIHSS score. Also take into account risk factors for thrombosis or bleeding (See Figure 15 in CCS guideline: <a href="https://www.onlinecjc.ca/action/showPdf?pii=S0828-282X%2820%2930991-0">https://www.onlinecjc.ca/action/showPdf?pii=S0828-282X%2820%2930991-0</a>).<sup>2</sup></li> <li>Elevated thromboembolic risk (e.g., <math>\geq 2\%</math> annual risk) according to a validated risk assessment tool.<sup>10</sup> <ul style="list-style-type: none"> <li>CHA<sub>2</sub>DS<sub>2</sub>-VASc score<sup>a</sup> of <math>\geq 2</math> or in men or <math>\geq 3</math> in women (recommended).<sup>10</sup> (also see <b>footnote b</b>)</li> <li>CHA<sub>2</sub>DS<sub>2</sub>-VASc score<sup>a</sup> of 1 in men or 2 in women (reasonable).<sup>10</sup> Give consideration to other risk factors that might affect risk (e.g., smoking, kidney disease, obesity, blood pressure control).<sup>10</sup> (also see <b>footnote b</b>)</li> <li>Canadian guidelines recommend using the CHAD-65 (CCS Algorithm) to guide decisions (Figure 8 in CCS guideline: <a href="https://www.onlinecjc.ca/action/showPdf?pii=S0828-282X%2820%2930991-0">https://www.onlinecjc.ca/action/showPdf?pii=S0828-282X%2820%2930991-0</a>).<sup>2</sup></li> </ul> </li> <li>hypertrophic cardiomyopathy.<sup>2,10</sup></li> <li>rheumatic mitral stenosis<sup>10</sup></li> <li>mitral stenosis of at least moderate severity<sup>10</sup></li> <li>mechanical heart valve.<sup>3</sup></li> <li>need for cardioversion (mechanical or pharmacologic) in stable patients. <ul style="list-style-type: none"> <li><b>Generally</b> anticoagulate for at least three weeks prior to and for at least four weeks afterward.<sup>2,10</sup> <ul style="list-style-type: none"> <li>Imaging is suggested to exclude cardiac thrombus in lieu of pre-cardioversion anticoagulation.<sup>2,10</sup> (AHA/ACC: Imaging/anticoagulation may not be needed in patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc <math>&lt; 2</math> and A-fib duration <math>&lt; 12</math> h because thrombus risk is low in these patients.<sup>10</sup>)</li> <li>Canada: it is suggested that cardioversion without three weeks of anticoagulation be reserved for patients: <ul style="list-style-type: none"> <li>presenting within 12 hrs of non-valvular A-fib onset who have not had a recent TIA or stroke.<sup>2</sup></li> <li>with nonvalvular A-fib and a CHADS<sub>2</sub> score <math>&lt; 2</math> who present between 12 and 48 hours of A-fib onset.<sup>2</sup></li> </ul> </li> </ul> </li> <li>If cardioversion will proceed without three weeks of anticoagulation, start anticoagulation before cardioversion.<sup>2,10</sup></li> <li>After cardioversion, base decisions about long-term anticoagulation as for other patients.<sup>2,10</sup></li> </ul> </li> <li>It may be reasonable to anticoagulate patients with a device-detected atrial high-rate episode lasting <math>\geq 24</math> hrs and a CHA<sub>2</sub>DS<sub>2</sub>-VASc score<sup>a</sup> <math>\geq 2</math> in men or <math>\geq 3</math> in women, or in higher risk patients with an episode lasting <math>\geq 5</math> min.<sup>10</sup></li> </ul> </li></ul>

Question	Answer/Pertinent Information
What are some considerations when choosing an antithrombotic for a patient with A-fib?	<ul style="list-style-type: none"> <li>• <b>Individualize</b> based on bleeding risk, cost, adherence, interactions, comorbidities, and patient preferences.<sup>10</sup></li> <li>• Our toolbox, <i>Appropriate Use of Anticoagulants</i>, provides information to help you choose an anticoagulant based on efficacy, comorbidities (e.g., <b>kidney</b> or <b>liver</b> impairment), other patient characteristics (e.g., body weight, age), and concomitant medications.</li> <li>• DOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) are <b>usually</b> preferred over warfarin, especially for patients who cannot maintain a therapeutic INR (e.g., time in therapeutic range &lt;65%).<sup>2,10</sup></li> <li>• For patients with <b>prosthetic heart valves</b>: <ul style="list-style-type: none"> <li>○ Mechanical valve: use warfarin.<sup>10</sup> Don't use DOACs; dabigatran and apixaban seem to increase thrombosis risk vs warfarin, and other DOACs have insufficient data in these patients.<sup>3,9,10</sup></li> <li>○ Bioprosthetic valve: DOACs can be used, but warfarin is preferred in the first three months.<sup>3,9,10,34</sup> A meta-analysis suggests a lower incidence of bioprosthetic mitral valve thrombosis with warfarin, but the authors advise individualization in anticoagulant choice.<sup>4</sup></li> </ul> </li> <li>• For patients with <b>rheumatic mitral stenosis</b>: warfarin.<sup>3</sup></li> <li>• For patients undergoing <b>cardioversion</b>: <ul style="list-style-type: none"> <li>○ use therapeutic-dose anticoagulation with warfarin, a DOAC (may be preferred over warfarin), or heparin.<sup>2,10</sup></li> </ul> </li> <li>• For patients with a <b>history of a major bleed</b>, see our FAQ, <i>Managing Bleeding with Anticoagulants</i>.<sup>43</sup></li> <li>• For patients with <b>antiphospholipid antibodies</b>: warfarin is preferred, especially in high-risk patients.<sup>8</sup></li> </ul>
How should anticoagulation be monitored?	<ul style="list-style-type: none"> <li>• Periodically assess appropriateness of anticoagulation (e.g., net clinical benefit, dosing, anticoagulant choice).<sup>2,10</sup></li> <li>• Patients with high risk of major bleeding may need to be monitored more often.<sup>2</sup> <ul style="list-style-type: none"> <li>○ Scores such as HAS-BLED<sup>d</sup> can be used to assess bleeding risk (high bleeding risk = HAS-BLED score <math>\geq 3</math>).<sup>2,10</sup></li> </ul> </li> <li>• When assessing net clinical benefit, keep in mind that bleeding risk scores (e.g., HAS-BLED<sup>d</sup>) include factors that increase both stroke risk and bleeding risk (e.g., age, kidney disease, hypertension).<sup>10</sup> It might be more useful to assess for factors that increase bleeding risk but not stroke risk (e.g., history of bleeding, anemia, medications [e.g., aspirin]) when evaluating risk/benefit.<sup>10</sup></li> <li>• Address potentially modifiable risk factors such as poorly controlled INR or blood pressure, alcohol use, aspirin or NSAID use, GI ulcer.<sup>2,10</sup> In kidney or liver impairment, ensure appropriate anticoagulant choice and dose.<sup>2</sup></li> <li>• For warfarin patients, check INR daily until stable, then every four to eight weeks, or every one to two weeks for unstable or unreliable patients.<sup>1</sup> The goal is to keep the INR in the therapeutic range (2 to 3) for A-fib <math>\geq 70\%</math> of the time.<sup>10</sup></li> <li>• DOACs may require baseline and periodic monitoring or dose adjustment for kidney or liver function. See our chart, <i>Comparison of Oral Anticoagulants</i>, for specific guidance, or Figure 11 in the AHA/ACC guidelines: <a href="https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000001193">https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000001193</a>.<sup>10</sup></li> </ul>

Question	Answer/Pertinent Information
What if anticoagulation requires interruption?	<ul style="list-style-type: none"> <li>• See our FAQ, <i>Managing Bleeding with Anticoagulants</i>, and our chart, <i>Perioperative Management of Chronic Medications in Noncardiac Surgery</i>.</li> </ul>
What if an anticoagulated patient requires an antiplatelet agent?	<ul style="list-style-type: none"> <li>• Control modifiable bleeding risk factors.<sup>2</sup></li> <li>• Consider PPI use.<sup>2</sup></li> <li>• Consider clopidogrel over prasugrel or ticagrelor if a P2Y12 inhibitor is indicated.<sup>2</sup></li> <li>• In warfarin patients, target the lower end of the therapeutic INR range (2 to 2.5).<sup>2</sup></li> <li>• In ACS or PCI patients who require DAPT, aspirin should be discontinued after one to four weeks of triple therapy, with continued use of the P2Y12 inhibitor (usually clopidogrel) and oral anticoagulant.<sup>6</sup> After six months, a DOAC alone may be appropriate.<sup>7</sup></li> </ul>
What is the target heart rate for patients with A-fib?	<ul style="list-style-type: none"> <li>• Resting HR &lt;100 bpm to 110 is a reasonable target, guided by patient symptoms.<sup>10</sup></li> <li>• For patients with arrhythmia-induced cardiomyopathy or recalcitrant HF symptoms, a reasonable target is &lt;80 bpm at rest or &lt;110 bpm during moderate exercise.<sup>10</sup></li> <li>• CCS: Resting HR ≤100 bpm is the recommended long-term target and when titrating rate-controlling agents in patients who present to the acute care setting with a primary diagnosis of A-fib.<sup>2</sup></li> </ul>
When is rhythm control a reasonable or preferred strategy?	<ul style="list-style-type: none"> <li>• Patient is hemodynamically unstable (electrical cardioversion is indicated).<sup>10</sup></li> <li>• Patient is highly symptomatic from A-fib, or to clarify whether symptoms are due to the patient's A-fib.<sup>10</sup></li> <li>• Patient is young, or athletic (consider catheter ablation).<sup>10</sup></li> <li>• Patient continues to have symptoms despite rate control.<sup>10</sup></li> <li>• Patient is newly diagnosed (&lt;1 year duration).<sup>2,10</sup> <ul style="list-style-type: none"> <li>○ For patients with high CV risk (&gt;75 years of age, prior TIA or stroke, or two of the following: age &gt;65 years, female, CHF, diabetes, hypertension, severe coronary artery disease, chronic kidney disease, left ventricular hypertrophy [diastolic septal wall width &gt;15 mm]), rhythm control plus usual care (rate control and anticoagulation) was more effective than usual care (NNT = 95 for five years to prevent one death, stroke, or hospitalization) [Evidence level B-1]. Antiarrhythmic side effects occurred in 2% of the rhythm control patients.<sup>35</sup></li> </ul> </li> <li>• Patient has left ventricular dysfunction or HF.<sup>10</sup></li> <li>• Patient prefers a rhythm control strategy.<sup>10</sup></li> <li>• Patient has a pre-excitation syndrome.<sup>10</sup></li> <li>• Patient has a small left atrium or marked atrioventricular regurgitation.<sup>10</sup></li> <li>• See the table below for pharmacologic options for cardioversion and maintenance of sinus rhythm.</li> </ul>

Question	Answer/Pertinent Information
What is the role of catheter ablation?	<ul style="list-style-type: none"> <li>Initial treatment with catheter cryoablation is associated with reduced atrial antiarrhythmia recurrence.<sup>37</sup></li> <li>Consider catheter ablation for young, healthy patients (e.g., athletes) with symptomatic paroxysmal A-fib with no or minimal structural heart disease.<sup>10</sup> <ul style="list-style-type: none"> <li>Younger patients have a long life expectancy during which to derive benefit (e.g., delayed A-fib progression).<sup>10</sup></li> </ul> </li> <li>Older adults can derive CV benefit from catheter ablation due to improved rhythm control.<sup>10</sup></li> <li>Consider catheter ablation when antiarrhythmic drugs are not effective, can't be used, or are not preferred.<sup>10</sup></li> <li>Catheter ablation is recommended for patients with pre-excitation.<sup>2,10</sup></li> <li>Consider catheter ablation for patients with HF (especially early stage HFrEF with minimal structural heart disease), or A-fib-associated cardiomyopathy.<sup>10</sup></li> <li>Be aware that ablation does not preclude the need for anticoagulation. Catheter ablation is performed under therapeutic anticoagulation. Anticoagulation is continued for at least three months. After that, decisions about anticoagulation are made as for other A-Fib patients (e.g., using CHA<sub>2</sub>DS<sub>2</sub>-VASc).<sup>10</sup></li> </ul>

### Comparison of Rate Control Medications for Atrial Fibrillation

---Information in chart may differ from product labeling and is not comprehensive.---

Drug	Consider for...	May not be appropriate in... <sup>c</sup>	Comments
Beta-blocker	<ul style="list-style-type: none"> <li>HFrEF.<sup>2,10</sup></li> <li>ACS.<sup>10</sup></li> <li>Thyrotoxicosis.<sup>10</sup></li> <li>Hypertrophic cardiomyopathy with symptomatic LVOTO (nonvasodilating BB).<sup>2,27</sup></li> <li>Pre-op (A-fib prophylaxis) or post-op cardiac surgery.<sup>10</sup></li> <li>Pregnancy.<sup>10</sup></li> <li>BTK inhibitor-induced A-fib.<sup>10</sup></li> </ul>	<ul style="list-style-type: none"> <li>Hemodynamic instability.<sup>10</sup></li> <li>Decompensated CHF.<sup>10</sup></li> <li>Asthma.<sup>10</sup></li> <li>Pre-excitation.<sup>10</sup></li> </ul>	<ul style="list-style-type: none"> <li>If IV used, start oral agent as soon as possible for uninterrupted control.<sup>2</sup> <b>See footnote f.</b></li> <li>For HFrEF, target an evidence-based dose.<sup>2</sup></li> <li>Consider nonselective beta-blocker (e.g., propranolol) for thyrotoxicosis.<sup>10</sup></li> <li>Consider propranolol or metoprolol for pregnant patients.<sup>10</sup></li> <li>Landilolol is an ultra-short acting beta-1 selective BB with RCT data in the cardiac surgery population.<sup>42,43</sup></li> </ul>
CCB (diltiazem or verapamil)	<ul style="list-style-type: none"> <li>Thyrotoxicosis (BB alternative).<sup>44</sup></li> <li>Hypertrophic cardiomyopathy with symptomatic LVOTO.<sup>27</sup></li> <li>Bronchospastic disease.<sup>44</sup></li> <li>Post-op cardiac surgery (BB alternative).<sup>10</sup></li> </ul>	<ul style="list-style-type: none"> <li>Hemodynamic instability.<sup>1</sup></li> <li>EF ≤40%.<sup>2,10</sup></li> <li>Pre-excitation.<sup>10</sup></li> </ul>	<ul style="list-style-type: none"> <li>If IV used, start oral agent as soon as possible for uninterrupted control.<sup>2</sup> <b>See footnote f.</b></li> <li>IV diltiazem seems to work faster than IV metoprolol (3 min vs 20 min), but with potentially more hypotension.<sup>32</sup></li> </ul>

Drug	Consider for...	May not be appropriate in... <sup>e</sup>	Comments
Amiodarone	<ul style="list-style-type: none"> <li>Acute rate control in decompensated HF, mild hypotension, or EF <math>\leq</math>40% (IV).<sup>2,10</sup></li> <li>Pre-op cardiac surgery (A-fib prophylaxis).<sup>10</sup></li> </ul>	<ul style="list-style-type: none"> <li>Pre-excitation.<sup>2,10</sup></li> <li>Contraindications: sick sinus syndrome, cardiogenic shock, bradycardia with syncope, second- or third-degree AV block (Canada [oral]: thyroid dysfunction, interstitial lung disease, hepatitis).<sup>13,15</sup></li> </ul>	<ul style="list-style-type: none"> <li>Should not generally be used for rate control.<sup>34</sup></li> <li>Rhythm control agent; risk of stroke with if non-anticoagulated patient converts.<sup>2</sup></li> <li>Drug interactions and adverse effects limit usefulness. See <b>footnote c</b>.</li> <li>If IV used, start oral agent as soon as possible for uninterrupted control.<sup>2</sup></li> </ul>
Digoxin	<ul style="list-style-type: none"> <li>Acute rate control in acute CHF, EF <math>\leq</math>40%, or mild hypotension (IV).<sup>2</sup></li> <li>Permanent A-fib in elderly or sedentary.<sup>2</sup></li> <li>Add or alternative to first-line agents.<sup>10</sup></li> <li>Pregnancy.<sup>10</sup></li> </ul>	<ul style="list-style-type: none"> <li>Obstructive hypertrophic cardiomyopathy.<sup>27</sup></li> <li>Pre-excitation.<sup>10</sup></li> </ul>	<ul style="list-style-type: none"> <li>Not a preferred option.<sup>10</sup></li> <li>Digoxin is less effective with a slower onset than BBs or CCBs.<sup>33</sup></li> <li>Can combine with BB or CCB.<sup>10</sup></li> <li>If IV used, start oral agent as soon as possible for uninterrupted control.<sup>2</sup></li> </ul>

### Antiarrhythmics for Atrial Fibrillation

--Information in chart may differ from product labeling and is not comprehensive.--

Drug/Role	May NOT be appropriate in... <sup>e</sup>	Comments
Flecaïnide  <ul style="list-style-type: none"> <li>Conversion<sup>10</sup></li> <li>Maintenance<sup>10</sup></li> </ul>	<ul style="list-style-type: none"> <li>CHF or EF <math>\leq</math>40%.<sup>2,10</sup></li> <li>Heart disease (coronary or structural).<sup>2,10</sup></li> <li>Sinus or AV node dysfunction, infranodal conduction disease, or Brugada syndrome.<sup>2</sup></li> <li>Second- or third-degree AV block, or bi- or trifascicular block (contraindications).<sup>23,24</sup></li> </ul>	<ul style="list-style-type: none"> <li>Low risk of QT prolongation and torsades (&lt;1%).<sup>17,38,39</sup></li> <li>Increased mortality risk in patients with history of MI.<sup>2</sup></li> <li>Mild to moderate negative inotrope.<sup>17</sup></li> <li>Visual impairment common.<sup>17</sup></li> <li><b>Must use with a BB, diltiazem or verapamil to prevent ventricular arrhythmias.</b> For cardioversion or “pill-in-pocket” (see below), start <math>\geq</math>30 min prior to flecaïnide use to prevent high ventricular rate.<sup>2,10,34</sup></li> <li>“Pill-in-the-pocket:” at-home use for symptomatic A-fib (once shown safe in a monitored setting).<sup>2,10</sup></li> <li>Among the agents with the best evidence for cardioversion.<sup>10</sup></li> <li>Metabolized by CYP2D6.<sup>10</sup></li> <li>Requires initial dose reduction in kidney impairment.<sup>23</sup></li> <li>Check trough periodically in severe kidney or liver impairment. Trough monitoring is also recommended with amiodarone, CHF, moderate kidney impairment, or elderly (Canada).<sup>23,24</sup> Therapeutic range may be 0.2 to 1 mcg/mL.<sup>23,24</sup></li> </ul>
Propafenone	<ul style="list-style-type: none"> <li>Heart disease (coronary or structural).<sup>10</sup></li> </ul>	<ul style="list-style-type: none"> <li>Low risk of QT prolongation and torsades.<sup>38</sup></li> </ul>

Drug/Role	May NOT be appropriate in... <sup>e</sup>	Comments
<ul style="list-style-type: none"> <li>• Conversion<sup>10</sup></li> <li>• Maintenance<sup>10</sup></li> </ul>	<ul style="list-style-type: none"> <li>• HF (Canada: severe or uncontrolled), cardiogenic shock, cardiac impulse generation or conduction disorders (without a pacemaker), bradycardia, Brugada syndrome, bronchospasm, severe COPD, marked hypotension or electrolyte imbalance (Canada: myocardial infarction in the past three months, myasthenia gravis, or severe liver impairment) (contraindications).<sup>5,25</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Dysgeusia common.<sup>17</sup></li> <li>• <b>Must use with a BB, diltiazem or verapamil to prevent ventricular arrhythmias.</b> For cardioversion or “pill-in-pocket” (see below), start <math>\geq 30</math> min prior propafenone use to prevent high ventricular rate.<sup>2,10,34</sup></li> <li>• “Pill-in-the-pocket:” at-home use for symptomatic A-fib (once shown safe in a monitored setting).<sup>2,10</sup></li> <li>• Metabolized primarily by CYPD6, and to a lesser extent by CYP3A4 and CYP1A2.<sup>17</sup> Avoid use with both a CYP2D6 and CYP3A4 inhibitor.<sup>25</sup></li> <li>• Increases digoxin level via p-glycoprotein inhibition.<sup>17</sup></li> <li>• Inhibits warfarin metabolism via CYP2C9 inhibition. Expect a 25% increase in prothrombin time.<sup>17</sup></li> </ul>
Dofetilide (US) <ul style="list-style-type: none"> <li>• Maintenance<sup>10</sup></li> </ul>	<ul style="list-style-type: none"> <li>• QT prolongation. Contraindicated if QTc <math>&gt;440</math> ms (500 ms in patients with ventricular conduction abnormalities).<sup>20</sup></li> <li>• Severe kidney impairment (contraindicated if CrCl <math>&lt;20</math> mL/min).<sup>20</sup></li> <li>• Hypokalemia or hypomagnesemia.<sup>10</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Option for patients with HF<math>\neq</math>EF<sup>10</sup> or hypertrophic cardiomyopathy.<sup>2</sup></li> <li>• Effective for conversion to sinus rhythm, but impractical because it takes days to work.<sup>10</sup></li> <li>• High risk of QT prolongation (19%) and torsades (3%).<sup>38,40</sup></li> <li>• Requires at least a three-day hospital stay for initiation and dose escalation to monitor ECG, serum potassium and magnesium, and CrCl.<sup>10</sup></li> <li>• Monitor ECG, potassium, magnesium, and kidney function at least every three to six months.<sup>10</sup></li> <li>• Dose based on kidney function and QTc.<sup>20</sup></li> <li>• Contraindicated with drugs that impair its kidney elimination (e.g., verapamil, cimetidine, trimethoprim, prochlorperazine, dolutegravir, megestrol, hydrochlorothiazide, ketoconazole).<sup>20</sup></li> <li>• Stop amiodarone at least three months prior to initiation.<sup>20</sup></li> </ul>
Dronedaronе <ul style="list-style-type: none"> <li>• Maintenance<sup>10</sup></li> </ul> <i>Continued...</i>	<ul style="list-style-type: none"> <li>• CHF (EF <math>\leq 40\%</math>).<sup>2,10</sup> Canadian labeling: any CHF.<sup>22</sup></li> <li>• Recent decompensation (hospitalized) or Class IV HF. Contraindications due to increased risk of death.<sup>21,22</sup></li> <li>• HR <math>&lt;50</math> bpm, second- or third-degree heart block, or sick sinus syndrome (contraindications).<sup>21,22</sup></li> </ul>	<ul style="list-style-type: none"> <li>• QT prolongation common (28%).<sup>17</sup> Low risk of torsades.<sup>38</sup></li> <li>• Similar to amiodarone, but without iodine and with a shorter half-life (~24 hrs).<sup>2</sup> Contraindicated in patients with a history of amiodarone-induced lung or liver toxicity.<sup>21,22</sup></li> <li>• Can cause bradycardia.<sup>10</sup></li> <li>• CYP3A4 substrate (metabolism inhibited by diltiazem, verapamil).<sup>17</sup> Contraindicated with strong CYP3A4 inhibitors.<sup>21,22</sup></li> <li>• Moderate CYP3A4 and CYP2D6 inhibitor.<sup>17</sup> Inhibits p-glycoprotein.<sup>17</sup> Increases BB and digoxin levels.<sup>17</sup></li> </ul>



Drug/Role	May NOT be appropriate in... <sup>e</sup>	Comments
Dronedaron, continued	<ul style="list-style-type: none"> <li>• Permanent A-fib. Contraindication due to increased risk of CV death, stroke, and HF hospitalization.<sup>21,22</sup></li> <li>• Patients with QTc <math>\geq 500</math> ms, or with other QT-prolonging meds or herbs (contraindications).<sup>21,22</sup></li> <li>• Liver impairment (contraindicated in severe liver impairment).<sup>21,22</sup></li> </ul>	<ul style="list-style-type: none"> <li>• May slightly increase SCr due to inhibition of tubular secretion of creatinine, without a decrease in kidney function.<sup>17</sup></li> <li>• Check liver function tests periodically, especially during the first six months (CCS: every three months for the first year, then every six months).<sup>2,21,22</sup></li> </ul>
Ibutilide	<ul style="list-style-type: none"> <li>• History of symptomatic CHF or EF <math>\leq 40\%</math>.<sup>2,10</sup></li> <li>• QT prolongation.<sup>2</sup></li> <li>• Suspected ACS.<sup>2</sup></li> <li>• Patients with hypokalemia or hypomagnesemia.<sup>2</sup></li> </ul>	<ul style="list-style-type: none"> <li>• High risk of QT prolongation (1.2%) and torsades (4.3%).<sup>17,38</sup></li> <li>• ECG monitoring required for at least four hours after administration.<sup>2</sup></li> <li>• May cause hypotension.<sup>2</sup></li> <li>• IV magnesium, before +/- after treatment, may improve efficacy and safety.<sup>2,10</sup></li> <li>• Faster response than amiodarone, but higher risk of QT prolongation and torsades.<sup>10</sup></li> <li>• Improves efficacy of electrical cardioversion.<sup>2</sup></li> <li>• Option for hemodynamically stable patients with pre-excitation, and for A-fib post-cardiac surgery.<sup>2,10</sup></li> </ul>
Procainamide	<ul style="list-style-type: none"> <li>• Complete heart block, torsades, or lupus (contraindications).<sup>31</sup></li> <li>• EF <math>\leq 40\%</math>.<sup>10</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Reserve for patients in whom ibutilide or amiodarone are not appropriate.<sup>10</sup></li> <li>• Risk of QT prolongation and torsades appear low.<sup>11,28</sup></li> <li>• Hypotension may limit its use.<sup>41</sup></li> <li>• Appropriate for hemodynamically stable patients with pre-excitation (IV).<sup>2,10</sup></li> <li>• Less effective than ibutilide.<sup>10</sup></li> </ul>
Sotalol	<ul style="list-style-type: none"> <li>• Cardiogenic shock or decompensated HF (Canada: severe HF)(contraindicated).<sup>29,30</sup></li> <li>• EF <math>\leq 40\%</math>.<sup>2</sup></li> <li>• Bronchospastic disease (contraindicated).<sup>29,30</sup></li> <li>• QT prolongation (contraindicated)<sup>29,30</sup> or risks for torsades.<sup>2</sup></li> <li>• Bradycardia, second- or third-degree AV block, or sick sinus syndrome (contraindicated).<sup>29,30</sup></li> <li>• Serum potassium <math>&lt; 4</math> mEq (mmol)/L (Canada:hypokalemia)(contraindicated).<sup>29,30</sup></li> </ul>	<ul style="list-style-type: none"> <li>• High risk of QT prolongation (4% to 12%) and torsades (0.6% to 4%).<sup>17</sup></li> <li>• Moderately lower risk of torsades than ibutilide.<sup>38</sup></li> <li>• May cause bradycardia.<sup>10</sup></li> <li>• Requires dose reduction in kidney impairment.<sup>10</sup></li> <li>• Do not use with a beta-blocker. Avoid in HFrEF because these patients should be taking an evidence-based BB.<sup>10</sup></li> <li>• Inpatient initiation recommended for at least three days for initiation or reloading to monitor ECG and CrCl.<sup>10</sup> CSS: if started as an outpatient, check ECG at baseline and 48 to 72 hours after initiation.<sup>2</sup></li> <li>• Monitor ECG, potassium, magnesium, and kidney function at least every three to six months.<sup>10</sup></li> <li>• Option for mild hypertrophic cardiomyopathy.<sup>2</sup></li> </ul>

Drug/Role	May NOT be appropriate in... <sup>e</sup>	Comments
Amiodarone  • Conversion <sup>10</sup> • Maintenance <sup>10</sup>	• Pre-excitation. <sup>2,10</sup> • Contraindications: sick sinus syndrome, cardiogenic shock, bradycardia with syncope, second- or third-degree AV block (Canada [oral]: thyroid dysfunction, interstitial lung disease, hepatitis). <sup>13,15</sup>	• QT prolongation occurs infrequently, and torsades is rare (~7%). <sup>2,10</sup> • High efficacy, but usually a last-line option; <b>drug interactions and adverse effects limit usefulness.</b> <sup>10,34</sup> See footnote c. • Consider for: <ul style="list-style-type: none"> <li>○ hypertrophic cardiomyopathy<sup>2</sup></li> <li>○ CHF<sup>10</sup></li> </ul> • Improves efficacy of electrical cardioversion. <sup>2</sup> • Slow onset (eight to 12 hours IV). <sup>10</sup> • Comparable hospitalization and mortality rates to rate control. <sup>14</sup>

- a. **CHA<sub>2</sub>DS<sub>2</sub>-VASc score:** CHF = 1 point; Hypertension = 1 point; Age 75 or older = 2 points; Diabetes = 1 point; prior Stroke, TIA, or thromboembolism = 2 points; Vascular disease (aortic plaque, peripheral artery disease, or history of MI) = 1 point; Age 65 to 74 years = 1 point; Sex category female = 1 point. Scores correlate with approximate annual stroke risk (based on a 2001 hospitalized cohort) of 0% for score of 0, 1.3% for score of 1, 2.2% for score of 2, 3.2% for score of 3, 4% for score of 4, 6.7% for score of 5, 9.8% for score of 6, 9.6% for score of 7, 6.7% for score of 8, and 15.2% for score of 9. An online calculator is available at <http://www.mdcalc.com/cha2ds2-vasc-score-for-atrial-fibrillation-stroke-risk/>. The CHA<sub>2</sub>DS<sub>2</sub>-VASc score is **not** for use in patients with mechanical heart valve or moderate to severe mitral stenosis.<sup>5</sup> These patients were excluded from DOAC clinical trials.
- b. CHA<sub>2</sub>DS<sub>2</sub>-VASc has the most data and was used in most clinical trials of A-fib treatment. Other validated clinical risk scores include ATRIA and GARFIELD-AF. ATRIA and GARFIELD-AF include kidney disease and advanced age (≥85 years) as risk factors. GARFIELD also gives consideration to the impact of bleeding history, dementia, and smoking.<sup>10</sup>
- c. **Amiodarone:**
- **Side effects:** About 50% of patients have side effects.<sup>12</sup> Due to amiodarone's ~60-day mean half-life, side effects may persist for several weeks to months after stopping it.<sup>13,15</sup> With IV administration, the most common adverse effects are hypotension, bradycardia, and phlebitis.<sup>2</sup> Causes bradycardia in 5%, and ventricular arrhythmias (e.g., torsades de pointes) in <1% of patients.<sup>10,12</sup> **Pulmonary toxicity** occurs in up to 2% of patients, and may occur as early as two weeks into treatment.<sup>16,18</sup> Potentially fatal.<sup>12</sup> Dose-dependent blue **skin discoloration** in <10% of patients; slow reversal (over years) with discontinuation.<sup>12,15</sup> Advise sunscreen use or sun avoidance due to **photosensitivity**.<sup>12</sup> Incidence of **hyperthyroidism** may be as high as 12%.<sup>12</sup> Incidence of **hypothyroidism** may be as high as 22%.<sup>12</sup> Hypothyroidism is more common, but hyperthyroidism is more dangerous.<sup>12</sup>
  - **Drug interactions:**
    - Amiodarone inhibits multiple enzymes (e.g., CYP3A, CYP2C9, CYP2D6), and transporters (e.g., p-glycoprotein). Substrate of CYP2C8 and CYP3A4.<sup>17</sup>
    - Among DOACs, apixaban appears to be the least likely to interact.<sup>36</sup> Kidney function affects the significance of the interaction with other DOACs.<sup>36</sup> Avoid rivaroxaban with amiodarone if CrCl is <80 mL/min.<sup>36</sup> Avoid dabigatran for A-fib if CrCl <30 mL/min.<sup>36</sup>

- When starting amiodarone, doses of other drugs may need to be decreased (e.g., decrease oral digoxin by 30% to 50%; decrease IV digoxin by 15% to 30%; decrease flecainide dose by 50%; decrease warfarin by 33% to 50%).<sup>17</sup>
- Once amiodarone is initiated, expect to make INR-guided warfarin dose reductions weekly for the next six to eight weeks.<sup>19</sup> Thereafter, the warfarin dose will need to be increased gradually, per INR measurements, as the amiodarone dose is adjusted downward.<sup>19</sup> Expect dose reductions (relative to baseline) of 25%, 30%, 35%, or 40% for patients taking amiodarone 100 mg, 200 mg, 300 mg, or 400 mg daily, respectively.<sup>19</sup>
- Limit the dose of simvastatin to 20 mg daily, and lovastatin to 40 mg daily.<sup>17</sup>
- Advise patients to avoid grapefruit juice.<sup>17</sup>
- Must be avoided with many hepatitis C drugs due to risk of dangerous bradycardia.
- **Monitoring:**
  - **Liver function** tests: baseline and every six months.<sup>12</sup> Transaminase elevation >2 times normal occurs in 15% to 30% of patients, but hepatitis/cirrhosis occurs <3% of patients.<sup>12</sup> If hepatotoxicity is suspected (e.g., clinical signs and symptoms or hepatitis), consider discontinuation and/or investigation for cirrhosis.<sup>12</sup> Also consider discontinuation or dose reduction if levels are significantly (>3 times normal, or twice normal in patient with baseline elevation) or persistently elevated.<sup>13,15</sup>
  - **Pulmonary function:** chest x-ray at baseline and yearly.<sup>12</sup> Baseline pulmonary function tests, including D<sub>L</sub>CO.<sup>12</sup> Repeat if pulmonary toxicity suspected (e.g., unexplained cough or dyspnea; abnormal x-ray).<sup>12</sup> In the event of toxicity, discontinue amiodarone and consider prednisone 40 to 60 mg daily for four to eight weeks, followed by a taper.<sup>12</sup>
  - **Electrocardiogram:** baseline, after starting, yearly, and when clinically indicated.<sup>12,18</sup>
  - **Thyroid function:** baseline TSH, free T4, and total or free T3, and then TSH every six months.<sup>12</sup> Thyrotoxicosis may require amiodarone discontinuation, and/or medical or surgical treatment.<sup>26</sup> Management options for hypothyroidism include discontinuation or levothyroxine.<sup>12</sup>
  - **Eye exam:** baseline, yearly, and in the event of visual changes.<sup>12,18</sup> Optic neuropathy requires discontinuation.<sup>12</sup>
- d. HAS-BLED score: systolic blood pressure >160 mm Hg = 1 point; severe kidney disease (SCr >2.26 mg/dL [200 umol/L], dialysis, or kidney transplant) or severe liver disease (bilirubin 2 x normal, transaminases 3 x normal, or cirrhosis) = 1 point each; stroke = 1 point; bleeding history = 1 point; labile INR (time in range <60%) = 1 point; age ≥65 years = 1 point; antiplatelet or NSAID = 1 point; alcohol excess (>8 drinks/week) = 1 point.<sup>10</sup> An online calculator is available at <https://www.mdcalc.com/calc/807/has-bleed-score-major-bleeding-risk>.
- e. Consult labeling for a complete list of contraindications.
- f. For help switching from IV to PO BB or CCB, see <https://cardiq.org/wp-content/uploads/resources/Atrial-Fibrillation-Mgt%20-%20Emergency-Department-Management-of-Atrial-Fibrillation-Algorithm-190312.pdf>. If switching from **landiolol**, reduce rate by 50% ten minutes after the first dose of oral beta-blocker.<sup>41</sup> Stop landiolol when heart rate has been at goal for at least one hour.<sup>41</sup>

**Abbreviations:** ACS = acute coronary syndrome; A-fib = atrial fibrillation; A-flutter = atrial flutter; AHA/ACC = American Heart Association/American College of Cardiology; BB = beta-blocker; bpm = beats per minute; BTK = Bruton's tyrosine kinase; CCB = calcium channel blocker; CCS = Canadian Cardiovascular Society; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; CrCl = creatinine clearance; CV = cardiovascular; D<sub>L</sub>CO = diffusion capacity of carbon monoxide; DOAC = direct-acting oral anticoagulant; ECG = electrocardiogram; EF = ejection fraction; GI = gastrointestinal; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; HR = heart rate; INR = international normalized ratio; IV = intravenous; LVOTO = left ventricular outflow tract obstruction; RCT = randomized controlled trial; SCr = serum creatinine; TIA = transient ischemic attack

*Users of this resource are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication.*

### Levels of Evidence

In accordance with our goal of providing Evidence-Based information, we are citing the **LEVEL OF EVIDENCE** for the clinical recommendations we publish.

Level	Definition	Study Quality
<b>A</b>	Good-quality patient-oriented evidence.*	<ol style="list-style-type: none"> <li>1. High-quality randomized controlled trial (RCT)</li> <li>2. Systematic review (SR)/Meta-analysis of RCTs with consistent findings</li> <li>3. All-or-none study</li> </ol>
<b>B</b>	Inconsistent or limited-quality patient-oriented evidence.*	<ol style="list-style-type: none"> <li>1. Lower-quality RCT</li> <li>2. SR/Meta-analysis with low-quality clinical trials or of studies with inconsistent findings</li> <li>3. Cohort study</li> <li>4. Case control study</li> </ol>
<b>C</b>	Consensus; usual practice; expert opinion; disease-oriented evidence (e.g., physiologic or surrogate endpoints); case series for studies of diagnosis, treatment, prevention, or screening.	

**\*Outcomes that matter to patients** (e.g., morbidity, mortality, symptom improvement, quality of life).

[Adapted from Ebell MH, Siwek J, Weiss BD, et al. Strength of Recommendation Taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. *Am Fam Physician* 2004;69:548-56. <https://www.aafp.org/pubs/afp/issues/2004/0201/p548.html>.]

### References

1. UW Medicine. UW Medicine Anticoagulation Services. Warfarin (Coumadin). [https://sites.uw.edu/anticoag/drugs/warfarin/#Frequency\\_of\\_Monitoring](https://sites.uw.edu/anticoag/drugs/warfarin/#Frequency_of_Monitoring). (Accessed June 28, 2025).
2. Andrade JG, Aguilar M, Atzema C, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. *Can J Cardiol*. 2020 Dec;36(12):1847-1948.
3. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021 Feb 2;143(5):e72-e227. Erratum in: *Circulation*. 2021 Feb 2;143(5):e229. Erratum in: *Circulation*. 2023 Aug 22;148(8):e8. Erratum in: *Circulation*. 2023 Nov 14;148(20):e185. Erratum in: *Circulation*. 2024 Sep 17;150(12):e267.
4. Zorman MJ, Vibhishanan J, Dangas K, et al. Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis. *Eur Heart J Cardiovasc Pharmacother*. 2025 May 2;11(3):251-263.
5. Product monograph for Rythmol. BGP Pharma. Etobicoke, ON M8Z 2S6. August 2021
6. Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2025 Apr;151(13):e771-e862. Erratum in: *Circulation*. 2025 Apr;151(13):e865. Erratum in: *Circulation*. 2025 Jun 24;151(25):e1098.
7. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation*. 2023 Aug 29;148(9):e9-e119. Erratum in: *Circulation*. 2023 Sep 26;148(13):e148. doi: 10.1161/CIR.0000000000001183. Erratum in: *Circulation*. 2023 Dec 5;148(23):e186.

8. Thrombosis Canada. Thrombophilia: antiphospholipid antibody syndrome. September 10, 2024.  
[https://thrombosiscanada.ca/clinical\\_guides/pdfs/AN\\_TIPHOSPHOLIPIDANTIBODYSYNDRO\\_35.pdf](https://thrombosiscanada.ca/clinical_guides/pdfs/AN_TIPHOSPHOLIPIDANTIBODYSYNDRO_35.pdf). (Accessed June 29, 2025).
9. Thrombosis Canada. Bioprosthetic and mechanical heart valves: antithrombotic therapy. January 24, 2024.  
[https://thrombosiscanada.ca/clinical\\_guides/pdfs/AN\\_TITHROMBOTICDRUGMANAGEMENTIN\\_33.pdf](https://thrombosiscanada.ca/clinical_guides/pdfs/AN_TITHROMBOTICDRUGMANAGEMENTIN_33.pdf). (Accessed June 29, 2025).
10. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2024 Jan 2;149(1):e1-e156. Erratum in: *Circulation*. 2024 Jan 2;149(1):e167. Erratum in: *Circulation*. 2024 Feb 27;149(9):e936. Erratum in: *Circulation*. 2024 Jun 11;149(24):e1413.
11. Stiell IG, Sivilotti MLA, Taljaard M, et al. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial. *Lancet*. 2020 Feb 1;395(10221):339-349.
12. Epstein AE, Olshansky B, Naccarelli GV, et al. Practical Management Guide for Clinicians Who Treat Patients with Amiodarone. *Am J Med*. 2016 May;129(5):468-75.
13. Product monograph for Sandoz amiodarone. Sandoz Canada. Boucherville, QC J4B 1E6. May 2025.
14. Cadrin-Tourigny J, Wyse DG, Roy D, et al. Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials. *J Cardiovasc Electrophysiol*. 2014 Dec;25(12):1306-13.
15. Product information for Pacerone. Upsher-Smith Laboratories. Maple Grove, MN 55369. May 2023.
16. Kharabsheh S, Abendroth CS, Kozak M. Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone. *Am J Cardiol*. 2002 Apr 1;89(7):896-8.
17. Clinical Pharmacology powered by ClinicalKey. Tampa (FL): Elsevier. 2025.  
<http://www.clinicalkey.com>. (Accessed June 29, 2025).
18. Hamilton D Sr, Nandkeolyar S, Lan H, et al. Amiodarone: A Comprehensive Guide for Clinicians. *Am J Cardiovasc Drugs*. 2020 Dec;20(6):549-558.
19. Sanoski CA, Bauman JL. Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy. *Chest*. 2002 Jan;121(1):19-23.
20. Product information for Tikosyn. Pfizer. New York, NY 10001. February 2025.
21. Product information for Multaq. Sanofi-Aventis US. Morristown, NJ 07960. May 2025.
22. Product monograph for Multaq. Sanofi-Aventis Canada. Laval, QC H7V 0A3. October 2024.
23. Product information for flecainide. Epic Pharma. Laurelton, NY 11413. January 2024.
24. Product monograph for flecainide. Sanis Health. Brampton, ON L6Y 5S5. January 2023.
25. Product information for propafenone. Strides Pharma. East Brunswick, NJ 08816. May 2025.
26. Gopalan M, Burks J. Thyroid dysfunction induced by amiodarone therapy treatment & management. August 28, 2024.  
<https://emedicine.medscape.com/article/129033-treatment>. (Accessed June 30, 2025).
27. Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation*. 2024 Jun 4;149(23):e1239-e1311. Erratum in: *Circulation*. 2024 Aug 20;150(8):e198.
28. Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. *J Am Coll Cardiol*. 1998 May;31(6):1414-9.
29. Product information for Betapace/Betapace AF. Legacy Pharma. St. Michael. Barbados. BB14017. June 2023.
30. Product monograph for Apo-sotalol. Apotex. Weston, ON M9L 1T9. July 2022.
31. Product information for procainamide. Caplin Steriles USA. Hamilton, NJ 08619. July 2024.
32. Jaya F, Afzal M, Anusha F, et al. Efficacy and Safety of Intravenous Diltiazem Versus Metoprolol in the Management of Atrial Fibrillation with Rapid Ventricular Response in the Emergency Department: A Comprehensive Umbrella Review of Systematic Reviews and Meta-analyses. *J Innov Card Rhythm Manag*. 2024 Sep 15;15(9):6022-6036.
33. Alsagaff MY, Susilo H, Pramudia C, et al. Rapid Atrial Fibrillation in the Emergency Department. *Heart Int*. 2022 Jun 30;16(1):12-19.
34. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2024 Sep 29;45(36):3314-3414.
35. Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. *N Engl J Med*. 2020 Oct 1;383(14):1305-1316.
36. Wiggins BS, Dixon DL, Neyens RR, et al. Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2020 Mar 24;75(11):1341-1350.
37. Magnani S, Cappato R. Efficacy of cryoablation in atrial fibrillation: comparison with antiarrhythmic therapy. *Eur Heart J Suppl*. 2024 Apr 17;26(Suppl 1):i35-i38.
38. Verma A. Antiarrhythmic drugs. In: Bhatt DL. *Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease*. 9th ed. Elsevier, 2021:533-592.
39. Nasser M, Idris S, Marinelli K, Machado C. Flecainide-induced Torsades de Pointes: Case Report and

- Review of Literature. Rev Cardiovasc Med. 2015;16(3):214-20 [abstract].
40. Anand V, Vakil K, Tholakanahalli V, et al. Discontinuation of Dofetilide From QT Prolongation and Ventricular Tachycardia in the Real World. JACC Clin Electrophysiol. 2016 Dec;2(7):777-781.
41. Product information for Rapiblyk. AOP Orpham Pharmaceuticals. Leopold-Ungar-Platz 2. 1190 Vienna, Austria. November 2024.
42. Floria M, Oancea AF, Morariu PC, et al. An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting  $\beta_1$  Selective Antagonist) in Atrial Fibrillation. Pharmaceutics. 2024 Apr 8;16(4):517.
43. Levy B, Slama M, Lakbar I, et al. Landiolol for Treatment of New-Onset Atrial Fibrillation in Critical Care: A Systematic Review. J Clin Med. 2024 May 17;13(10):2951.
44. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014 Dec 2;130(23):e199-267. Erratum in: Circulation. 2014 Dec 2;130(23):e272-4.

***Cite this document as follows: Clinical Resource, Atrial Fibrillation: Focus on Pharmacotherapy. Pharmacist's Letter/Pharmacy Technician's Letter/Prescriber Insights. July 2025. [410764]***

—To access hundreds more clinical resources like this one, visit [trchealthcare.com](https://trchealthcare.com) to log in or subscribe—